PUBLISHER: The Business Research Company | PRODUCT CODE: 1948359
PUBLISHER: The Business Research Company | PRODUCT CODE: 1948359
Transfection reagents are substances or kits employed for introducing foreign genetic material, such as DNA or RNA, into cells. These reagents play a crucial role in facilitating the delivery of nucleic acids into cells, enabling researchers to explore gene expression, manipulate gene function, or produce recombinant proteins.
Within the realm of transfection reagents and equipment, the primary categories encompass instruments and reagents, along with kits. Transfection instruments are specialized laboratory tools designed to streamline the delivery of foreign nucleic acids, such as DNA or RNA, into cells during the transfection process. The range of molecules involved includes plasmid DNA, DNA oligonucleotides, small interfering RNA (siRNA), proteins, ribonucleoprotein complexes (RNPs), and others. Various organisms, including bacteria, mammalian cells, fungi, plants, and viruses, serve as recipients for these molecules. These products find application across diverse end-users, including biopharma, contract research organizations (CROs), contract manufacturing organizations (CMOs), contract development and manufacturing organizations (CDMOs), academia, hospitals, clinical labs, and others.
Tariffs are impacting the transfection reagents and equipment market by increasing costs of imported biochemical reagents, specialized polymers, lipid formulations, electroporation systems, and precision laboratory instruments. Research institutions and biopharmaceutical companies in North America and Europe are most affected due to reliance on imported high-grade reagents and equipment, while Asia-Pacific faces higher manufacturing input costs. These tariffs are increasing operational expenses and procurement timelines for laboratories. However, they are also encouraging domestic reagent production, regional manufacturing expansion, and local sourcing strategies that strengthen long-term supply chain stability.
The transfection reagents and equipment market research report is one of a series of new reports from The Business Research Company that provides transfection reagents and equipment market statistics, including transfection reagents and equipment industry global market size, regional shares, competitors with a transfection reagents and equipment market share, detailed transfection reagents and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the transfection reagents and equipment industry. This transfection reagents and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The transfection reagents and equipment market size has grown rapidly in recent years. It will grow from $1.74 billion in 2025 to $1.93 billion in 2026 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to expansion of molecular biology research activities, increasing use of cell-based assays, growth of recombinant protein production, rising academic and industrial genomics research, availability of advanced transfection chemistries.
The transfection reagents and equipment market size is expected to see rapid growth in the next few years. It will grow to $2.97 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to increasing adoption of CRISPR and gene therapy research, rising demand for scalable transfection platforms, expansion of biopharmaceutical pipeline development, growing investment in precision medicine, increasing automation in life science laboratories. Major trends in the forecast period include increasing adoption of high-efficiency transfection reagents, rising demand for gene editing-compatible delivery systems, growing use of non-viral transfection methods, expansion of automated transfection instruments, enhanced focus on cell-type specific transfection solutions.
The increasing number of cancer patients worldwide is expected to drive growth in the transfection reagents and equipment market in the coming years. Cancer comprises a group of diseases characterized by abnormal and uncontrolled cell growth. Transfection reagents are widely used in cancer research to introduce foreign genetic material, such as plasmid DNA or RNA molecules, allowing researchers to study gene expression, gene silencing, drug screening, and target validation. For example, in July 2024, Cancer Research UK, a UK-based cancer charity, projected that cancer incidence rates in the United Kingdom will rise for most types between 2023-2025 and 2038-2040, with increases ranging from less than 1% for breast cancer to 50% for eye cancer, while a smaller number of cancers are expected to decline, with reductions ranging from 2% for lung cancer to 27% for mesothelioma. Thus, the growing number of cancer patients worldwide is fueling growth in the transfection reagents and equipment market.
Key companies in the transfection reagents and equipment market are focusing on innovations such as GMP-grade AAV transfection reagents to enhance viral vector production efficiency and support large-scale gene therapy manufacturing. A GMP-grade AAV transfection reagent is a regulatory-compliant formulation designed to deliver genetic material efficiently into suspension cell cultures for scalable production of recombinant adeno-associated virus vectors. For example, in July 2025, Yeasen Biotechnology, a China-based biotechnology manufacturer, received U.S. FDA Drug Master File acceptance for its UltraAAV PEI Transfection Reagent-GMP grade. The reagent demonstrates substantially higher viral titers and improved full capsid ratios across multiple adeno-associated virus serotypes, offering superior performance compared with standard formulations. It also enhances manufacturing efficiency by achieving comparable vector yields with reduced reagent usage while meeting strict regulatory and quality standards suitable for clinical and commercial gene therapy production.
In March 2023, Sartorius AG, a Germany-based analytical laboratory instrument manufacturing company, acquired Polyplus-Transfection SA for $2.6 billion. This acquisition positions Sartorius AG strongly in the rapidly expanding cell and gene therapy markets, supporting business growth and meeting the escalating demand for cell and gene therapies. Polyplus-Transfection SA, a France-based biotechnology company, specializes in the development of transfection reagents and equipment.
Major companies operating in the transfection reagents and equipment market are Thermo Fisher Scientific Inc., Promega Corporation, Qiagen N.V., Bio-Rad Laboratories Inc., MaxCyte Inc., Lonza Group Ltd., Merck KGaA, Mirus Bio LLC, OriGene Technologies Inc., Altogen Biosystems, Applied Biological Materials Inc., Bex Co. Ltd., Takara Bio Inc., Polyplus-transfection SA, Sigma-Aldrich Corporation, Transfection Technologies Inc., Viromer, ABM Inc., chemicell GmbH, Genlantis, Biontech Laboratories GmbH, Jena Bioscience GmbH, PromoCell GmbH, PerkinElmer Inc., Sartorius AG, Hoffmann-La Roche Ltd., Bio-Techne Corporation, Biotium Inc., Cell Applications Inc.
North America was the largest region in the transfection reagents and equipment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transfection reagents and equipment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the transfection reagents and equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The transfection reagents and equipment market consists of sales of lipid-based transfection reagents, cationic polymer-based transfection reagents, calcium phosphate-based transfection reagents, viral transduction tools, transfection control plasmids, transfection validation tools, and electroporation systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Transfection Reagents And Equipment Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses transfection reagents and equipment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for transfection reagents and equipment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The transfection reagents and equipment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.